IM Cannabis (IMCC) Income from Non-Controlling Interests (2021 - 2026)
IM Cannabis (IMCC) posted quarterly Income from Non-Controlling Interests of $95266.0 for Q2 2025, up 130.51% year-over-year from $41327.5 in Q2 2024, and up 130.51% quarter-over-quarter from -$312197.0 in Q2 2024.
IM Cannabis (IMCC) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
IM Cannabis' Income from Non-Controlling Interests history runs 5 years deep, the most recent figure standing at $95266.0 for Q2 2025.
- In Q2 2025, Income from Non-Controlling Interests rose 130.51% year-over-year to $95266.0; the TTM figure through Jun 2025 stood at -$730758.8 (up 39.07% YoY), while the FY2025 annual figure was -$309064.2, up 68.14% from the prior year.
- Income from Non-Controlling Interests for Q2 2025 stood at $95266.0, up from -$312197.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $572483.9 in Q2 2023, with the low at -$1.1 million in Q2 2022.
- The 5-year median for Income from Non-Controlling Interests is -$312197.0 (2024), against an average of -$220833.6.
- The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests plunged 190.92% in 2022, then surged 152.7% in 2023.
- IM Cannabis' Income from Non-Controlling Interests stood at -$373409.0 in 2021, then slumped by 190.92% to -$1.1 million in 2022, then soared by 152.7% to $572483.9 in 2023, then slumped by 154.53% to -$312197.0 in 2024, then surged by 130.51% to $95266.0 in 2025.
- Business Quant data shows IMCC's Income from Non-Controlling Interests at $95266.0 in Q2 2025, -$312197.0 in Q2 2024, and $572483.9 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | IM Cannabis | 535,526.41 | -633,443.76 | 1.09 Mn | -137,355.80 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -137,355.80 |
| Jun 30, 2025 | 95,266.05 |
| Jun 30, 2024 | -312,197.01 |
| Jun 30, 2023 | 572,483.95 |
| Jun 30, 2022 | -1.09 Mn |
| Jun 30, 2021 | -373,408.97 |